Ultrasound Guided Upper Sacro-iliac Joint Injection For Low back pain

Ultrasound Guided Upper Sacro-iliac Joint Periarticular Injection For Pain Associated With Sacro-Iliac Joint Arthropathy: A Pilot Study

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/088626

Enrollment

Registered

2025-06-11

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M255- Pain in joint

Interventions

Intervention1: USG guided upper sacro-iliac joint injection.: USG guided upper sacro-iliac joint injection utilizing depotmethylprednisolone and local anaesthetics. A total of 20 mg of Depot methyl pr

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients has chronic sacroiliitis by history (paramedian low back pain with tenderness over S.I. joint confirmed also confirmed by physical examination). 2. Failed conservative therapy e.g. bed rest, anti-inflammatory medications and physical therapy for at least 6 weeks.

Exclusion criteria

Exclusion criteria: • Patients BMI above 35 kg/m2 • Coagulopathy. • Renal or Hepatic Failure. • Current Pregnancy or actively pursuing pregnancy. • Known allergy to local anesthetic or steroids. • Infection at site of needle placement or SIJ infection. • Prior surgical procedures involving the SIJ. • Previous surgical Fixation involving the lumbar spine.

Design outcomes

Primary

Measure	Time frame
Primary Objectives – To asses Numerical rating scale (NRS) following USG guided upper SIJ peri-articular injection. Timepoint: At 1 and 3 month interval post procedure	—

Secondary

Measure	Time frame
Secondary objectives – 1) To evaluate the functional status by modified Oswestry low back pain disability questionnaire (MODQ) at baseline, 1 month and 3 months interval. 2) Assessment of treatment response on the basis of Global perceived effect (GPE) scale at baseline, 1 month and 3 months interval. 3) To evaluate the anxiety and depression utilizing HADS scale at baseline, 1 month and 3 months interval. 4) To asses side effects & complications [if any]Timepoint: At 1 and 3 month interval post procedure	—

Measure

Time frame

Secondary objectives – 1) To evaluate the functional status by modified Oswestry low back pain disability questionnaire (MODQ) at baseline, 1 month and 3 months interval. 2) Assessment of treatment response on the basis of Global perceived effect (GPE) scale at baseline, 1 month and 3 months interval. 3) To evaluate the anxiety and depression utilizing HADS scale at baseline, 1 month and 3 months interval. 4) To asses side effects & complications [if any]Timepoint: At 1 and 3 month interval post procedure

—

Countries

India

Contacts

Public ContactDr Ravi Shankar Sharma

All India Institute of Medical Sciences, Rishikesh

drravishankarsharma4u@gmail.com9993116929

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026